CharlesJoelRosserMDMBA

Urology • Los Angeles, CA

Surgical Oncology

Professor and Medical Director Cedars-Sinai CANCER Clinical Trials Office

Join to view full profile

Dr. Rosser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rosser's full profile

Already have an account?

Office
8700 Beverly Blvd
Los Angeles, CA 90048

Summary

Dr. Charles Rosser is an urologist in Los Angeles, CA and is affiliated with Cedars-Sinai Medical Center. He received his medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 23 years. He specializes in surgical oncology and is experienced in bladder tumors, clinical research, and turbt.

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Urologic Surgical Oncology, 2000 - 2003
Wake Forest University Baptist Medical CenterResidency, Urology, 1994 - 2000
Rutgers Robert Wood Johnson Medical SchoolClass of 1994

Certifications & Licensure

CA State Medical License 2018 - 2026
HI State Medical License 2013 - 2024
FL State Medical License 2003 - 2023
NC State Medical License 2005 - 2017
TX State Medical License 2000 - 2017
American Board of Urology Urology

Clinical Trials

Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer Start of enrollment: 2003 Nov 01
Completed
Phase 2
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
Completed
Phase 1, Phase 2
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Unknown status
Phase 1, Phase 2
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer Start of enrollment: 2014 Jul 21
Recruiting
Phase 1, Phase 2
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2017 Feb 06
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Assessing the Causal Relationship between Waterpipe Smoking and Bladder Cancer.
Charles J Rosser
Cancer Epidemiology, Biomarkers & Prevention. 2024-04-03
1 citations
Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms.
Hideki Furuya, Toru Sakatani, Sunao Tanaka, Kaoru Murakami, Richard T Waldron
Journal of Translational Medicine. 2024-01-02
N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review.
Karim Chamie, Sam S Chang, Charles J Rosser, Eugene Kramolowski, Mark L Gonzalgo
Future Oncology. 2024-01-01

Press Mentions

New Bladder Cancer Diagnostic Receives Approval for Sale in EuropeJune 22nd, 2022
Nonagen Bioscience Announces CE Mark for Oncuria® Bladder Cancer DiagnosticJune 16th, 2022
Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer TestMay 12th, 2022
Join now to see all

Grant Support

Multiplexed protein biomarker for the non-invasive detection of bladder cancerNCI2016–2021